iShares Biotechnology ETF
IBB
Market cap $7.25B

144.36 USD

-3.36

2.27%

At close Nov 12, 4:00 PM EST

After hours

144.20

-0.16

0.11%

1 day

-2.27%

5 days

-2.20%

1 month

-0.93%

3 months

1.98%

6 months

7.40%

Year to date

4.56%

1 year

25.07%

5 years

30.78%

10 years

46.07%

0

Funds holding %

of 6,759 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 11 [Q1] → 11 (+0) [Q2]

0% less funds holding

Funds holding: 880 [Q1] → 879 (-1) [Q2]

1% less first-time investments, than exits

New positions opened: 77 | Existing positions closed: 78

2.61% less ownership

Funds ownership: 78.59% [Q1] → 75.97% (-2.61%) [Q2]

6% less capital invested

Capital invested by funds: $6.05B [Q1] → $5.66B (-$385M) [Q2]

38% less repeat investments, than reductions

Existing positions increased: 201 | Existing positions reduced: 323

76% less call options, than puts

Call options by funds: $301M | Put options by funds: $1.27B

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for IBB.

See Analyst Rankings

Financial journalist opinion

Biotechnology Stocks Eyeing Seasonality Move Higher

I have commented but not focused too much on the Biotechnology Sector ETF (IBB). My weekend comments were, “IBB remains stuck in its weekly trading range.

Biotechnology Stocks Eyeing Seasonality Move Higher

IBB: A Near-20x P/E Is Historically Pricey, Technical Trends Neutral

I reiterate a hold rating on IBB due to its stretched valuation at nearly 20x earnings and mixed technical situation. Despite a 7% YTD gain, IBB has underperformed the S&P 500, which is up 21%, and shows negative alpha. Key support and resistance levels to watch are $138-$141 and $150, respectively, with a potential bullish move to $160.

IBB: A Near-20x P/E Is Historically Pricey, Technical Trends Neutral

Zacks Investment Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Making its debut on 02/05/2001, smart beta exchange traded fund iShares Biotechnology ETF (IBB) provides investors broad exposure to the Health Care ETFs category of the market.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05/2001.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Biotech Boom Ahead? Key Stocks and ETFs to Watch Now

As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last Wednesday, several new opportunities and sector bull and bear markets might begin.

Biotech Boom Ahead? Key Stocks and ETFs to Watch Now

Biotech Breakout: Stocks for Your Watchlist

After a prolonged consolidation and downtrend following the pandemic-driven surge, the biotechnology sector is readying for a potential breakout and shifting its narrative. Represented by the iShares Biotechnology ETF NASDAQ: IBB, the sector has turned a significant corner, with previous resistance levels becoming support, setting the stage for a potential momentum shift.

Biotech Breakout: Stocks for Your Watchlist

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

Thanks to the prospect of lower interest rates, shares of biotech companies have doubled the gains of the broad market over the past few months.

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

The Motley Fool

3 ETFs for Growth Investors to Buy and Hold for Decades

Exchange-traded funds aren't just for risk-averse investors. Many funds can give exposure to some great growth stocks.

3 ETFs for Growth Investors to Buy and Hold for Decades

CNBC Television

Biotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle Ross

Michelle Ross, Stempoint Capital, joins 'Closing Bell' to discuss Eli Lilly after the stock saw a slight dip after rallying.

Biotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle Ross

Zacks Investment Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

See News Rankings

Charts implemented using Lightweight Charts™